ATE70439T1 - Verwendung von acetyl-l-carnitin zur herstellung eines medikamentes zur therapeutischen behandlung von peripheren neuropathien. - Google Patents

Verwendung von acetyl-l-carnitin zur herstellung eines medikamentes zur therapeutischen behandlung von peripheren neuropathien.

Info

Publication number
ATE70439T1
ATE70439T1 AT87830298T AT87830298T ATE70439T1 AT E70439 T1 ATE70439 T1 AT E70439T1 AT 87830298 T AT87830298 T AT 87830298T AT 87830298 T AT87830298 T AT 87830298T AT E70439 T1 ATE70439 T1 AT E70439T1
Authority
AT
Austria
Prior art keywords
carnitine
acetyl
medication
manufacture
therapeutic treatment
Prior art date
Application number
AT87830298T
Other languages
English (en)
Inventor
Menotti Calvani
Luigi Mosconi
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE70439T1 publication Critical patent/ATE70439T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
AT87830298T 1986-08-04 1987-07-31 Verwendung von acetyl-l-carnitin zur herstellung eines medikamentes zur therapeutischen behandlung von peripheren neuropathien. ATE70439T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT48358/86A IT1196564B (it) 1986-08-04 1986-08-04 Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
EP87830298A EP0256999B1 (de) 1986-08-04 1987-07-31 Verwendung von Acetyl-L-Carnitin zur Herstellung eines Medikamentes zur therapeutischen Behandlung von peripheren Neuropathien

Publications (1)

Publication Number Publication Date
ATE70439T1 true ATE70439T1 (de) 1992-01-15

Family

ID=11266089

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87830298T ATE70439T1 (de) 1986-08-04 1987-07-31 Verwendung von acetyl-l-carnitin zur herstellung eines medikamentes zur therapeutischen behandlung von peripheren neuropathien.

Country Status (11)

Country Link
US (1) US4751242A (de)
EP (1) EP0256999B1 (de)
JP (1) JPH085786B2 (de)
AT (1) ATE70439T1 (de)
CA (1) CA1298197C (de)
DE (1) DE3775301D1 (de)
DK (1) DK164641C (de)
ES (1) ES2039262T3 (de)
GR (1) GR3003405T3 (de)
IT (1) IT1196564B (de)
ZA (1) ZA875643B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1224842B (it) * 1988-12-27 1990-10-24 Sigma Tau Ind Farmaceuti Uso di derivati della l-carnitina nel trattamento terapeutico delle alterazioni degenerative del sistema nervoso
US5641764A (en) * 1989-03-31 1997-06-24 Peter Maccallum Institute Halogenated DNA ligand radiosensitizers for cancer therapy
IT1230141B (it) * 1989-05-03 1991-10-14 Fidia Spa Impiego di derivati della fosfatidil carnitina per la preparazione di composizioni farmaceutiche aventi attivita' nella terapia delle patologie dell'uomo associate con un danno neuronale.
IT1244636B (it) * 1991-01-04 1994-08-08 Sigma Tau Ind Farmaceuti Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
IT1245699B (it) * 1991-05-29 1994-10-14 Sigma Tau Ind Farmaceuti Derivati della l-carnitina quali agenti terapeutici per il trattamento delle miopatie, della degenarazione neuronale e per inibire la proteolisi
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
IT1294227B1 (it) * 1997-08-01 1999-03-24 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l-carnitina e alcoli alifatici a lunga catena utile per la prevenzione
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
JPH11298323A (ja) 1998-04-16 1999-10-29 Nec Yamagata Ltd 高速ロックアップpll回路
US20030199535A1 (en) * 1998-07-30 2003-10-23 Claudio Cavazza Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
ES2235499T3 (es) * 1998-07-30 2005-07-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Uso de derivados de propionil l-carnitina y de acetil l-carnitina en la preparacion de medicamentos con actividad anticancerigena.
IT1306178B1 (it) * 1999-07-27 2001-05-30 Sigma Tau Ind Farmaceuti Uso della l-carnitina e dei suoi alcanoil derivati per la preparazionedi un medicamento utile nel trattamento del paziente affetto da
US6562869B1 (en) * 1999-09-23 2003-05-13 Juvenon, Inc. Nutritional supplement for increased energy and stamina
WO2001021208A1 (en) * 1999-09-23 2001-03-29 Juvenon Corporation Nutritional supplement for increased energy and stamina
ITRM20010294A1 (it) * 2001-05-29 2002-11-29 Sigma Tau Ind Farmaceuti Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re
ITRM20010293A1 (it) * 2001-05-29 2002-11-29 Sigma Tau Ind Farmaceuti Uso della acetil-l-carnetina per la preparazione di un medicamento per la prevenzione del dolore.
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
ITRM20040327A1 (it) * 2004-07-01 2004-10-01 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici.
EP1874288B1 (de) * 2005-04-26 2013-07-17 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Acetyl l-carnitin zur vorbeugung schmerzhafter periphärer diabetischer neuropathie
US8569366B2 (en) * 2005-04-26 2013-10-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes
US20080161604A1 (en) * 2005-04-26 2008-07-03 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl L-Carnitine For Preventing Painful Peripheral Diabetic Neuropathy
JP2006347935A (ja) * 2005-06-15 2006-12-28 Masanori Ogata 炎症性サイトカインの産生が関与する疾患の予防及び/又は治療のための医薬
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
MX2012014127A (es) 2010-06-16 2013-06-28 Sigma Tau Ind Farmaceuti Acetil-carnitina para uso en un metodo para incrementar neurogenesis en tejido nervioso.
DK3277273T3 (da) * 2015-03-31 2020-04-14 Kolinpharma S P A Sammensætning til behandling af neuropatier og/eller neuropatisk smerte
US10036011B2 (en) * 2016-02-11 2018-07-31 Qiagen Waltham, Inc. Scavenger compounds for improved sequencing-by-synthesis
KR20230011999A (ko) 2020-05-15 2023-01-25 알파시그마 에스.피.에이. 메틸폴레이트를 포함하는 조성물
IT202200022437A1 (it) 2022-11-02 2024-05-02 Chiesi Italia S P A Composizione farmaceutica comprendente l-acetilcarnitina e beta-cariofillene

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism

Also Published As

Publication number Publication date
DK403587A (da) 1988-02-05
EP0256999A2 (de) 1988-02-24
CA1298197C (en) 1992-03-31
ES2039262T3 (es) 1993-09-16
EP0256999A3 (en) 1989-05-31
GR3003405T3 (en) 1993-02-17
ZA875643B (en) 1988-11-30
US4751242A (en) 1988-06-14
IT1196564B (it) 1988-11-16
JPS6344522A (ja) 1988-02-25
EP0256999B1 (de) 1991-12-18
JPH085786B2 (ja) 1996-01-24
IT8648358A0 (it) 1986-08-04
DK164641C (da) 1992-12-14
DE3775301D1 (de) 1992-01-30
DK164641B (da) 1992-07-27
DK403587D0 (da) 1987-08-03

Similar Documents

Publication Publication Date Title
ATE70439T1 (de) Verwendung von acetyl-l-carnitin zur herstellung eines medikamentes zur therapeutischen behandlung von peripheren neuropathien.
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
ATE292463T1 (de) L-carnitin oder ihre derivate und resveratrol oder ihre derivate zur vorbeugung und behandlung von kardiovaskulären erkrankungen, peripheren gefässkrankheit, peripheren diabetischen neuropathie und diese enthaltende pharmazeutische zusammensetzungen
DE3876877D1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
DE236684T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
ATE324884T1 (de) Verwendung von gamma-linolensäure oder dihomogammalinolensäure zur herstellung eines medikaments zur behandlung von huntington's chorea
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
MY101207A (en) Treatment of diseases caused by retroviruses
DE68911891D1 (de) Verwendung von Acetyl-L-carnitin zur Behandlung von Katarakt, sowie pharmazeutische Zusammensetzungen für eine derartige Behandlung.
ATE119770T1 (de) Verwendung von acetyl l-carnitin zur therapeutischen behandlung von coma.
ATE206914T1 (de) Verwendung von ursolsäure zur herstellung eines arzneimittels zur unterdrückung von metastasen
DK207889D0 (da) Farmaceutisk praeparat med anti-cancer virkning
SE8103003L (sv) Terapeutisk forfarande for behandling av diabetes och farmaceutisk komposition for genomforande av forfarandet
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE3850154D1 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
AR041947A1 (es) Uso de acetil-l-carnitina o de una sal farmaceuticamente aceptable de la misma para la preparacion de un medicamento para prevenir y/o tratar las neuropatias perifericas inducidas por la administracion de un agente anticancer que induce neuropatias perifericas
DE69015910D1 (de) Pharmazeutische Verwendung von Fettsäuren.
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
DE68910010D1 (de) Verwendung von Dapiprazol zur Herstellung eines Arzneimittels zur Verhinderung des Toleranzentwicklung bei der analgetischen Behandlung mit Morphin.
DE3688787D1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
ATE79750T1 (de) Pharmazeutische zusammensetzung mit antikrebswirkung und methode fuer die behandlung von krebs.
RU93016030A (ru) Лекарственное средство, стимулирующее гранулоцитарный росток кроветворения при цитостатических миелодепрессиях
RU92013625A (ru) Лекарственное средство, стимулирующее эритроидный росток кроветворения при цитостатических миелодепрессиях
KR930019207A (ko) 카르니틴 결핍 hiv-혈청양성 환자 치료용 l-카르니틴의 용도
ATE105192T1 (de) Methode fuer die kontrolle von chronischer atmungskrankheit und nekrotischer enteritis bei voegeln.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time